Fluorescein (FITC)

Fluorescein, often utilized in the form of fluorescein isothiocyanate (FITC), serves as a synthetic hapten target within modular or "universal" chimeric antigen receptor (CAR) T-cell therapy systems (Tamada et al., 2012). In these platforms, T cells are genetically engineered to express a CAR that specifically recognizes the fluorescein molecule rather than a native tumor antigen (Lee et al., 2016). The therapeutic process requires the administration of bispecific "adapter molecules," which consist of a fluorescein moiety conjugated to a tumor-targeting ligand such as folic acid, a small molecule, or a monoclonal antibody (NIH NCI Thesaurus). These adapters act as a bridge, simultaneously binding to the anti-fluorescein CAR-T cells and the tumor-associated antigens on the cancer cell surface. This cross-linking induces the formation of an immunological synapse, leading to T-cell activation, cytokine secretion, and targeted tumor cell lysis (Frontiers in Immunology, 2020). This modular design offers significant advantages, including the ability to target multiple antigens with a single CAR-T product and the capacity to control the intensity of the immune response by adjusting the adapter dosage (AACR, 2019). Clinical development of this system includes trials for osteosarcoma and other solid tumors using adapters like EC17 (folate-FITC) (ClinicalTrials.gov NCT05312411).

Other names

Fluorescein isothiocyanateFITCFluorescein tagHapten tagFluorescein on adapter molecules

The anti-fluorescein CAR-T cell recognizes the fluorescein moiety on a bispecific adapter molecule. The adapter molecule simultaneously binds to a tumor-associated antigen (TAA) on the cancer cell surface. This dual binding creates a bridge that cross-links the CAR-T cell to the tumor cell, forming an immunological synapse that triggers T-cell signaling, cytokine release, and cytotoxic activity against the target cell.